Catalyst Pharmaceuticals Inc (CPRX)
Cash conversion cycle
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 91.22 | 89.74 | 86.17 | 114.51 | 93.57 | 69.64 | 91.58 | 98.04 | 72.22 | 85.22 | 109.40 | 123.71 | 131.26 | 130.72 | 144.11 | 91.20 | 99.63 | 104.60 | 39.07 | 46.92 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | days | 91.22 | 89.74 | 86.17 | 114.51 | 93.57 | 69.64 | 91.58 | 98.04 | 72.22 | 85.22 | 109.40 | 123.71 | 131.26 | 130.72 | 144.11 | 91.20 | 99.63 | 104.60 | 39.07 | 46.92 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 91.22 + — – —
= 91.22
Catalyst Pharmaceuticals Inc's cash conversion cycle has experienced fluctuations over the years. The cash conversion cycle represents the time it takes for a company to convert its investments in inventory into cash flows from sales.
Observing the data provided, there has been a mix of improvements and deteriorations in Catalyst Pharmaceuticals Inc's cash conversion cycle. From March 31, 2020, to December 31, 2024, the cycle ranged from a low of 39.07 days to a high of 144.11 days. Notably, the trend shows some volatility, with occasional spikes followed by declines in the cycle duration.
It is important to highlight that a shorter cash conversion cycle is generally considered favorable as it indicates that the company is efficiently managing its working capital, turning inventory into cash more quickly. Conversely, a longer cycle suggests inefficiencies in managing inventory, collecting receivables, or both.
In conclusion, while the data provided indicates fluctuations in Catalyst Pharmaceuticals Inc's cash conversion cycle, a thorough analysis of the company's operational and financial performance would be necessary to understand the factors driving these changes and their implications for the company's overall financial health.
Peer comparison
Dec 31, 2024